RAYVOW 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0005 
C.I.11.b - Introduction of, or change(s) to, the 
08/02/2024 
n/a 
The RMP version 1.1 has been updated to include a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
descriptive interim analysis in the study design of study 
H8H-MC-B006 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
II/0004 
Update of sections 4.5 and 5.2 of the SmPC in order 
14/12/2023 
SmPC and PL 
Update of sections 4.5 and 5.2 of the SmPC in order to add 
drug-drug interaction information with dabigatran and 
rosuvastatin.  
SmPC new text 
For more information, please refer to the Summary of 
Product Characteristics. 
to add drug-drug interaction information with 
dabigatran and rosuvastatin based on the results 
from study LAIO, An Open-Label, 2-Part Study to 
Investigate the Effect of Lasmiditan on the 
Pharmacokinetics of Dabigatran and Rosuvastatin in 
Healthy Volunteers. The aim of study LAIO was to 
investigate the effect of lasmiditan on the 
pharmacokinetic profiles of dabigatran (a P-
glycoprotein substrate) and rosuvastatin (breast 
cancer resistance protein substrate) in healthy 
volunteers. The Package Leaflet is updated 
accordingly. In addition, the MAH took the 
opportunity to introduce minor editorial changes to 
the PI. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/11011
Periodic Safety Update EU Single assessment - 
26/10/2023 
n/a 
PRAC Recommendation - maintenance 
/202304 
lasmiditan 
PSUSA/11011
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
/202210 
lasmiditan 
IA/0001 
B.II.d.2.a - Change in test procedure for the finished 
13/12/2022 
n/a 
product - Minor changes to an approved test 
procedure 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
